rizatriptan ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2393 144034-80-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • MK-0462
  • rizatriptan
  • risatriptan
  • rizatriptan benzoate
Rizatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
  • Molecular weight: 269.35
  • Formula: C15H19N5
  • CLOGP: 1.45
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 49.74
  • ALOGS: -2.90
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 42 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 14 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.86 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 29, 1998 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 385.03 13.80 259 15725 75021 50514119
Neovascularisation 115.72 13.80 32 15952 981 50588159
Paradoxical drug reaction 82.27 13.80 34 15950 3613 50585527
Headache 67.63 13.80 327 15657 506208 50082932
Drug ineffective for unapproved indication 51.18 13.80 47 15937 21234 50567906
Extrapyramidal disorder 49.49 13.80 36 15948 11734 50577406
Anuria 46.39 13.80 34 15950 11210 50577930
Gallbladder polyp 43.90 13.80 14 15970 707 50588433
Death 42.62 13.80 25 15959 325354 50263786
Nausea 41.68 13.80 371 15613 705027 49884113
Medication overuse headache 41.44 13.80 13 15971 622 50588518
Multiple sclerosis relapse 39.88 13.80 58 15926 42906 50546234
Hypermobility syndrome 39.19 13.80 13 15971 744 50588396
Dust allergy 38.75 13.80 12 15972 550 50588590
Serotonin syndrome 38.22 13.80 43 15941 24670 50564470
Pre-existing condition improved 37.55 13.80 25 15959 7072 50582068
Cholecystitis chronic 34.92 13.80 27 15957 9642 50579498
Product substitution issue 33.71 13.80 31 15953 14026 50575114
Contraindicated product administered 33.25 13.80 4 15980 148954 50440186
Coronary artery dissection 31.79 13.80 11 15973 716 50588424
Anaphylactic reaction 31.29 13.80 59 15925 53996 50535144
Purpura senile 31.09 13.80 10 15974 519 50588621
Anxiety 28.24 13.80 121 15863 177485 50411655
Depression 28.10 13.80 115 15869 165308 50423832
Carotid artery dissection 27.53 13.80 7 15977 154 50588986
Product physical issue 27.21 13.80 17 15967 4315 50584825
Dyspepsia 24.85 13.80 65 15919 74032 50515108
Cholelithiasis 23.93 13.80 43 15941 37930 50551210
Vomiting 23.88 13.80 236 15748 460522 50128618
Gait inability 23.42 13.80 42 15942 36985 50552155
Allergy to animal 22.98 13.80 9 15975 831 50588309
Tarsal tunnel syndrome 22.97 13.80 8 15976 531 50588609
Colitis ischaemic 22.90 13.80 21 15963 9462 50579678
Vestibular disorder 22.57 13.80 10 15974 1259 50587881
Migraine with aura 22.46 13.80 12 15972 2273 50586867
Product dose omission issue 22.44 13.80 116 15868 183722 50405418
Paraesthesia 22.34 13.80 86 15898 120157 50468983
Ankylosing spondylitis 21.60 13.80 18 15966 7147 50581993
Vertigo 21.12 13.80 49 15935 51783 50537357
Complex regional pain syndrome 21.10 13.80 11 15973 1982 50587158
Suicidal ideation 21.10 13.80 51 15933 55334 50533806
Dizziness 20.20 13.80 182 15802 346187 50242953
Oesophagitis ulcerative 20.01 13.80 7 15977 471 50588669
Stress 19.92 13.80 49 15935 53744 50535396
Abdominal pain 19.78 13.80 135 15849 236093 50353047
Somnolence 19.75 13.80 99 15885 154886 50434254
Toxicity to various agents 19.55 13.80 23 15961 212476 50376664
Sensory level abnormal 19.49 13.80 5 15979 114 50589026
Feeling abnormal 18.79 13.80 84 15900 125408 50463732
Acute kidney injury 18.60 13.80 27 15957 228031 50361109
Synovitis 18.46 13.80 8 15976 123857 50465283
Sinusitis 18.36 13.80 104 15880 170454 50418686
Weight decreased 18.26 13.80 126 15858 221119 50368021
Alopecia 18.10 13.80 31 15953 245016 50344124
Resorption bone increased 18.09 13.80 8 15976 1003 50588137
Vasospasm 18.07 13.80 7 15977 628 50588512
Anaemia 17.69 13.80 33 15951 252423 50336717
Sepsis 17.67 13.80 10 15974 132915 50456225
Sleep apnoea syndrome 17.62 13.80 29 15955 23839 50565301
Platelet count decreased 17.59 13.80 5 15979 100721 50488419
Febrile neutropenia 16.77 13.80 5 15979 97662 50491478
Muscle spasms 16.56 13.80 81 15903 125472 50463668
Hemiparaesthesia 16.49 13.80 4 15980 72 50589068
Abdominal discomfort 16.48 13.80 30 15954 231611 50357529
Neutropenia 15.89 13.80 14 15970 147951 50441189
Wound 15.50 13.80 7 15977 105787 50483353
Broad ligament tear 15.35 13.80 3 15981 18 50589122
No adverse event 15.08 13.80 33 15951 33545 50555595
Emotional distress 15.01 13.80 30 15954 28633 50560507
Facial pain 14.88 13.80 15 15969 7594 50581546
Gallbladder disorder 14.66 13.80 22 15962 16720 50572420
Insomnia 14.66 13.80 100 15884 174765 50414375
Muscle twitching 14.56 13.80 21 15963 15410 50573730
Atrial fibrillation 14.49 13.80 7 15977 101738 50487402
Injury 14.48 13.80 41 15943 48884 50540256
Pleural effusion 14.30 13.80 4 15980 81450 50507690
Oral pruritus 14.25 13.80 8 15976 1670 50587470
Palate injury 13.82 13.80 3 15981 32 50589108

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nightmare 108.45 27.86 36 1700 11381 29561410
Sedation 93.61 27.86 36 1700 17369 29555422
Nephrolithiasis 83.78 27.86 37 1699 25297 29547494
Nausea 73.58 27.86 87 1649 289168 29283623
Migraine 67.82 27.86 26 1710 12404 29560387
Hyperhidrosis 65.69 27.86 43 1693 64497 29508294
Renal infarct 40.02 27.86 10 1726 1147 29571644
Therapy partial responder 39.92 27.86 14 1722 5185 29567606
Paraesthesia 30.00 27.86 25 1711 53820 29518971
Drug ineffective 29.34 27.86 65 1671 363105 29209686
Product used for unknown indication 27.89 27.86 6 1730 356 29572435

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 386.88 15.08 211 13481 62466 64422574
Neovascularisation 125.63 15.08 32 13660 1071 64483969
Nausea 78.19 15.08 351 13341 785449 63699591
Paradoxical drug reaction 71.86 15.08 32 13660 6088 64478952
Headache 65.40 15.08 253 13439 529214 63955826
Hypermobility syndrome 49.11 15.08 13 13679 507 64484533
Dust allergy 48.33 15.08 15 13677 1038 64484002
Drug ineffective for unapproved indication 44.19 15.08 43 13649 31090 64453950
Death 42.42 15.08 25 13667 482680 64002360
Gallbladder polyp 41.89 15.08 13 13679 899 64484141
Medication overuse headache 40.68 15.08 12 13680 698 64484342
Anuria 40.48 15.08 33 13659 18931 64466109
Extrapyramidal disorder 37.54 15.08 32 13660 19520 64465520
Dyspepsia 36.47 15.08 63 13629 80249 64404791
Cholecystitis chronic 35.49 15.08 23 13669 9264 64475776
Coronary artery dissection 33.66 15.08 11 13681 899 64484141
Nightmare 33.61 15.08 31 13661 20962 64464078
Insomnia 32.44 15.08 104 13588 197732 64287308
Nephrolithiasis 32.28 15.08 43 13649 43640 64441400
Colitis ischaemic 32.18 15.08 25 13667 13389 64471651
Purpura senile 30.88 15.08 9 13683 502 64484538
Acute kidney injury 28.57 15.08 32 13660 449208 64035832
Multiple sclerosis relapse 28.13 15.08 39 13653 41096 64443944
Paraesthesia 28.02 15.08 77 13615 134445 64350595
Sedation 27.89 15.08 39 13653 41423 64443617
Product substitution issue 27.87 15.08 26 13666 17835 64467205
Depression 27.05 15.08 93 13599 183198 64301842
Drug ineffective 26.88 15.08 284 13408 839963 63645077
Tarsal tunnel syndrome 26.61 15.08 8 13684 497 64484543
Therapy partial responder 26.56 15.08 20 13672 10228 64474812
Vasospasm 25.50 15.08 9 13683 929 64484111
Carotid artery dissection 25.22 15.08 7 13685 327 64484713
Serotonin syndrome 25.02 15.08 36 13656 39246 64445794
Anaemia 24.03 15.08 27 13665 378653 64106387
Burns third degree 23.82 15.08 7 13685 402 64484638
Cholelithiasis 23.73 15.08 38 13654 45468 64439572
Migraine with aura 23.70 15.08 11 13681 2301 64482739
Complex regional pain syndrome 23.61 15.08 10 13682 1686 64483354
Ankylosing spondylitis 23.43 15.08 17 13675 8217 64476823
Vomiting 23.41 15.08 198 13494 550919 63934121
Anxiety 23.38 15.08 95 13597 202554 64282486
Nasal discharge discolouration 23.28 15.08 10 13682 1744 64483296
Sinusitis 23.26 15.08 76 13616 145852 64339188
Sepsis 23.08 15.08 10 13682 230331 64254709
Anaphylactic reaction 22.64 15.08 47 13645 68617 64416423
Febrile neutropenia 22.52 15.08 6 13686 187651 64297389
Abdominal pain 21.97 15.08 127 13565 312248 64172792
Allergy to animal 21.09 15.08 8 13684 1013 64484027
Hyperhidrosis 20.76 15.08 66 13626 124854 64360186
Sensory level abnormal 20.69 15.08 5 13687 134 64484906
Reversible cerebral vasoconstriction syndrome 20.52 15.08 10 13682 2332 64482708
Resorption bone increased 20.04 15.08 8 13684 1160 64483880
Pain 19.49 15.08 191 13501 553320 63931720
Hypotension 19.29 15.08 32 13660 380942 64104098
Toxicity to various agents 18.91 15.08 30 13662 363483 64121557
Neutropenia 18.86 15.08 14 13678 239610 64245430
Oesophagitis ulcerative 18.31 15.08 7 13685 905 64484135
Dizziness 17.95 15.08 154 13538 430009 64055031
Deep vein thrombosis 17.86 15.08 56 13636 105126 64379914
Atheroembolism 17.76 15.08 5 13687 246 64484794
Vestibular disorder 17.74 15.08 9 13683 2284 64482756
Thrombocytopenia 17.71 15.08 13 13679 223788 64261252
Nasal oedema 17.63 15.08 7 13685 1001 64484039
Weight decreased 17.44 15.08 112 13580 285627 64199413
Facial pain 17.40 15.08 14 13678 7881 64477159
Renal infarct 17.32 15.08 9 13683 2402 64482638
Emotional distress 17.31 15.08 29 13663 36009 64449031
Platelet count decreased 17.25 15.08 7 13685 167704 64317336
Renal impairment 16.81 15.08 4 13688 135013 64350027
Oral pruritus 16.70 15.08 8 13684 1797 64483243
Pancytopenia 16.42 15.08 5 13687 143304 64341736
Atrial fibrillation 16.25 15.08 8 13684 171081 64313959
Vision blurred 16.18 15.08 49 13643 90267 64394773
Gallbladder disorder 16.15 15.08 19 13673 17011 64468029
Head discomfort 16.14 15.08 16 13676 11818 64473222
Injury 15.80 15.08 36 13656 55956 64429084
Vertigo 15.62 15.08 37 13655 58974 64426066
Product used for unknown indication 15.35 15.08 6 13686 824 64484216
Blood creatinine increased 15.09 15.08 5 13687 135777 64349263

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02CC04 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35941 serotonin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Prinzmetal angina contraindication 87343002
Chronic renal failure syndrome contraindication 90688005
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.75 acidic
pKa2 8.28 Basic
pKa3 3.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 7.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 5.10 CHEMBL
Cytochrome P450 2D6 Enzyme Ki 4.85 WOMBAT-PK
5-hydroxytryptamine receptor 1F GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 1E GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 1A GPCR Ki 6.85 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.10 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.20 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 7.30 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel IC50 5.40 CHEMBL

External reference:

IDSource
4021122 VUID
N0000148576 NUI
D00675 KEGG_DRUG
145202-66-0 SECONDARY_CAS_RN
4021122 VANDF
4021123 VANDF
C0297635 UMLSCUI
CHEBI:48273 CHEBI
CHEMBL905 ChEMBL_ID
CHEMBL1201032 ChEMBL_ID
DB00953 DRUGBANK_ID
C093622 MESH_SUPPLEMENTAL_RECORD_UI
5078 PUBCHEM_CID
51 IUPHAR_LIGAND_ID
7474 INN_ID
51086HBW8G UNII
237082 RXNORM
196735 MMSL
7484 MMSL
d04328 MMSL
007571 NDDF
007572 NDDF
108411001 SNOMEDCT_US
108412008 SNOMEDCT_US
363573000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 0006-0266 TABLET 5 mg ORAL NDA 27 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 0006-0267 TABLET 10 mg ORAL NDA 27 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 0006-3800 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 27 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 0006-3801 TABLET, ORALLY DISINTEGRATING 10 mg ORAL NDA 27 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7471 TABLET 5 mg ORAL ANDA 25 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7472 TABLET 10 mg ORAL ANDA 25 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1403 TABLET 5 mg ORAL ANDA 28 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1404 TABLET 10 mg ORAL ANDA 28 sections
MAXALT-MLT HUMAN PRESCRIPTION DRUG LABEL 1 16590-144 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 29 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 16590-461 TABLET 10 mg ORAL NDA 29 sections
MAXALT HUMAN PRESCRIPTION DRUG LABEL 1 21695-956 TABLET 10 mg ORAL NDA 29 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-268 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-269 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-316 TABLET 5 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 29300-317 TABLET 10 mg ORAL ANDA 23 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 31722-462 TABLET 5 mg ORAL ANDA 19 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 31722-463 TABLET 10 mg ORAL ANDA 19 sections
Rizatriptan Human Prescription Drug Label 1 33342-087 TABLET, FILM COATED 5 mg ORAL ANDA 25 sections
Rizatriptan Human Prescription Drug Label 1 33342-088 TABLET, FILM COATED 10 mg ORAL ANDA 25 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-093 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 25 sections
rizatriptan benzoate Human Prescription Drug Label 1 33342-094 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 25 sections
RIZATRIPTAN BENZOATE HUMAN PRESCRIPTION DRUG LABEL 1 43817-133 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 21 sections
RIZATRIPTAN BENZOATE HUMAN PRESCRIPTION DRUG LABEL 1 43817-135 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 21 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 45865-825 TABLET 10 mg ORAL ANDA 25 sections
Rizatriptan Benzoate Human Prescription Drug Label 1 50090-3343 TABLET 10 mg ORAL ANDA 24 sections
Rizatriptan Benzoate Human Prescription Drug Label 1 50090-3367 TABLET 10 mg ORAL ANDA 25 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3921 TABLET 10 mg ORAL ANDA 27 sections
rizatriptan benzoate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4619 TABLET 10 mg ORAL ANDA 26 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 51991-354 TABLET 5 mg ORAL ANDA 28 sections
Rizatriptan Benzoate HUMAN PRESCRIPTION DRUG LABEL 1 51991-355 TABLET 10 mg ORAL ANDA 28 sections